# Eltrombopag Phase III Study In Chinese Chronic ITP Patients

> **NCT01762761** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 155 (actual)

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

## Interventions

- **DRUG:** eltrombopag
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01762761
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-18
- **Primary completion:** 2014-06-05
- **Final completion:** 2018-11-22
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762761, "Eltrombopag Phase III Study In Chinese Chronic ITP Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01762761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*